Literature DB >> 17182659

Group B streptococcus prevalence in pregnant women from North-Eastern Italy: advantages of a screening strategy based on direct plating plus broth enrichment.

Marina Busetti1, Pierlanfranco D'Agaro, Cesare Campello.   

Abstract

AIMS: To assess the sensitivity of a combined selective broth enrichment technique plus selective plating for the detection of group B streptococcus (GBS) colonisation in a large cohort of pregnant women from North-Eastern Italy.
METHODS: During 2002-2005, 5020 pregnant women were screened between the 35th and the 37th week of gestation. A lower vaginal sample and a rectal sample were collected and inoculated onto LIM broth and a selective colistin aztreonam blood agar plate (CAP). Direct agar plates were examined after 18-24 hours and, if negative, after 48 hours. LIM broth was subcultured after 18-24 hours onto a Columbia blood agar plate. All colonies suggestive for GBS were submitted to phenotypic identification.
RESULTS: 901 Women (17.9%) were positive for GBS. On 728 positive samples, corresponding to patients enrolled between 2003 and 2005, the results of selective direct plating and selective broth enrichment were compared. A total of 561 (77.1% of positive samples, corresponding to 13.9% of patients) were positive on direct selective agar; an additional 167 isolates (22.9% of samples, 4.1% of patients) were recovered from the LIM broth subculture.
CONCLUSIONS: The prevalence of GBS carriage in this population-based study is a reliable estimate considering the sensitivity of the microbiological methods used, the rate of attendance of pregnant women to clinical and laboratory settings and the compliance to the protocol. Results confirm that the combination of selective enrichment broth and selective direct plating is a time-saving and sensitive method.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182659      PMCID: PMC2014865          DOI: 10.1136/jcp.2006.043489

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  29 in total

1.  Evaluation of methods to increase the sensitivity and timeliness of detection of Streptococcus agalactiae in pregnant women.

Authors:  Sue B Overman; Douglas D Eley; Barry E Jacobs; Julie A Ribes
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  ACOG Committee Opinion: number 279, December 2002. Prevention of early-onset group B streptococcal disease in newborns.

Authors: 
Journal:  Obstet Gynecol       Date:  2002-12       Impact factor: 7.661

3.  Use of direct latex agglutination testing of selective broth in the detection of group B strepptococcal carriage in pregnant women.

Authors:  C Guerrero; J Martínez; A Menasalvas; R Blázquez; T Rodríguez; M Segovia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-06       Impact factor: 3.267

4.  Method for quantitative detection and presumptive identification of group B streptococci on primary plating.

Authors:  Søren Mose Hansen; Uffe B Skov Sørensen
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  Use of GBS media for rapid detection of group B streptococci in vaginal and rectal swabs from women in labor.

Authors:  M Votava; M Tejkalová; M Drábková; V Unzeitig; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-02       Impact factor: 3.267

6.  A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates.

Authors:  Stephanie J Schrag; Elizabeth R Zell; Ruth Lynfield; Aaron Roome; Kathryn E Arnold; Allen S Craig; Lee H Harrison; Arthur Reingold; Karen Stefonek; Glenda Smith; Melanie Gamble; Anne Schuchat
Journal:  N Engl J Med       Date:  2002-07-25       Impact factor: 91.245

7.  Comparison of direct selective versus nonselective agar media plus LIM broth enrichment for determination of group B streptococcus colonization status in pregnant women.

Authors:  Sameer Elsayed; Daniel B Gregson; Deirdre L Church
Journal:  Arch Pathol Lab Med       Date:  2003-06       Impact factor: 5.534

8.  Impact of different prevention strategies on neonatal group B streptococcal disease.

Authors:  Patrizia Vergani; Luisa Patanè; Carla Colombo; Cesarina Borroni; Giuseppe Giltri; Alessandro Ghidini
Journal:  Am J Perinatol       Date:  2002-08       Impact factor: 1.862

9.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC.

Authors:  Stephanie Schrag; Rachel Gorwitz; Kristi Fultz-Butts; Anne Schuchat
Journal:  MMWR Recomm Rep       Date:  2002-08-16

10.  Dynamics of Streptococcus agalactiae colonization in women during and after pregnancy and in their infants.

Authors:  Søren Mose Hansen; Niels Uldbjerg; Mogens Kilian; Uffe B Skov Sørensen
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more
  10 in total

1.  Preliminary evaluation of Hitchens-Pike-Todd-Hewitt medium (HPTH) for detection of Group B Streptococci in pregnant women.

Authors:  Maurício Chaves; Rubia A F Pádua; Paula A Z Campanerut; Sandra M Pelloso; Maria Dalva B Carvalho; Vera L D Siqueira; Regiane B L Scodro; Rosilene F Cardoso
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Screening of group B Streptococcus infection in pregnancy and neonatal outcomes in the province of Trento, Italy.

Authors:  Silvano Piffer; Roberto Rizzello; Mariangela Pedron; Laura Dellanna; Anna Lina Lauriola
Journal:  Infez Med       Date:  2022-06-01

3.  Evaluation of Trans-Vag broth, colistin-nalidixic agar, and CHROMagar StrepB for detection of group B Streptococcus in vaginal and rectal swabs from pregnant women in South Africa.

Authors:  Gaurav Kwatra; Shabir A Madhi; Clare L Cutland; Eckhart J Buchmann; Peter V Adrian
Journal:  J Clin Microbiol       Date:  2013-05-22       Impact factor: 5.948

4.  Evaluation of Culture, Antigen Detection and Polymerase Chain Reaction for Detection of Vaginal Colonization of Group B Streptococcus (GBS) in Pregnant Women.

Authors:  Kavitha Paul Konikkara; Shrikala Baliga; Suchithra Shenoy; B Bharati
Journal:  J Clin Diagn Res       Date:  2014-02-03

5.  Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry with Time-of-Flight Peak Analysis for Rapid and Accurate Detection of Group B Streptococcus in Pregnant Women.

Authors:  Daiki Tanno; Kyoichi Saito; Kazutaka Ohashi; Masahiro Toyokawa; Yukio Yamadera; Hiroki Shimura
Journal:  Microbiol Spectr       Date:  2022-04-18

6.  Prevalence and drug susceptibility pattern of group B Streptococci (GBS) among pregnant women attending antenatal care (ANC) in Nekemte Referral Hospital (NRH), Nekemte, Ethiopia.

Authors:  Hylemariam Mihiretie Mengist; Olifan Zewdie; Adugna Belew; Regea Dabsu
Journal:  BMC Res Notes       Date:  2017-08-10

7.  Group B streptococcal colonization: Prevalence and impact of smoking in women delivering term or near term neonates in a large tertiary care hospital in the southern United States.

Authors:  Philip Kum-Nji; Linda Meloy; John Pierce; Amanda Ritter; Rachel Wheeler
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

8.  Epidemiology of Toxoplasma and CMV serology and of GBS colonization in pregnancy and neonatal outcome in a Sicilian population.

Authors:  Giuseppe Puccio; Cinzia Cajozzo; Laura Antonella Canduscio; Lucia Cino; Amelia Romano; Maria Gabriella Schimmenti; Mario Giuffrè; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2014-02-22       Impact factor: 2.638

9.  Group B streptococci vaginal colonization and drug susceptibility pattern among pregnant women attending in selected public antenatal care centers in Addis Ababa, Ethiopia.

Authors:  Solomon Assefa; Kassu Desta; Tsehaynesh Lema
Journal:  BMC Pregnancy Childbirth       Date:  2018-05-04       Impact factor: 3.007

10.  Vagino-rectal colonization prevalence by Streptococcus agalactiae and its susceptibility profile in pregnant women attending a third-level hospital

Authors:  César Hernán Campo; María Fernanda Martínez; Juan Carlos Otero; Giovanna Rincón
Journal:  Biomedica       Date:  2019-12-01       Impact factor: 0.935

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.